Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
24 Maio 2023 - 9:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced that it will
participate in three upcoming investor conferences.
TD Cowen 4th Annual Oncology Innovation SummitTuesday, May 30,
20236:30AM PT/9:30AM ET
Jefferies Healthcare ConferenceFriday, June 9, 20239:45AM
PT/12:45PM ET
Goldman Sachs 44th Annual Global Healthcare ConferenceWednesday,
June 14, 20231:20PM PT/4:20PM ET
Any available webcasts will be posted to the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. Following a live webcast, a replay will be
available on the Company's website for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to develop allogeneic
CAR T products for cancer and the potential benefits of AlloCAR T.
Various factors may cause material differences between Allogene’s
expectations and actual results, including, risks and uncertainties
related to: our product candidates are based on novel technologies,
which makes it difficult to predict the time and cost of product
candidate development and obtaining regulatory approval. These
and other risks are discussed in greater detail in Allogene’s
filings with the SEC, including without limitation under the
“Risk Factors” heading of its Form 10-Q for the quarter
ended March 31, 2023. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024